“The results are not conclusive, but we strongly suspect that it is the psilocybin playing a role, because the quit rates are so much higher than even the best current psychological or pharmacological treatments for tobacco addiction, which are typically around 35%,” says Johnson. Based on the success of the initial trial, he and fellow researchers at Johns Hopkins have now embarked on a phase II randomised controlled trial with 80 participants, which started in October 2014.
Quelle: Psychedelics: entering a new age of addiction therapy | Feature | Pharmaceutical Journal
